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Dear Editors,
Kanis et al. erroneously state in a recent paper about the
diagnosis and management of osteoporosis in postmeno-
pausal women that 100 μg of PTH(1-84) is equivalent to
40 μg of teriparatide, PTH(1-34) [1]. This equivalence was
calculated from their respective molecular weights (4,115
for teriparatide [2], 9,426 for full-length PTH [3]) but does
not consider bioavailability. The bioavailability of PTH(1-34)
and PTH(1-84) are 95% and 55%, respectively [4, 5].
Bioequivalence requires that the number of PTH(1-34) and
PTH(1-84)moleculesshouldbethesame:NPTH(1-34)=NPTH(1-84)
The clinical dose is based on molecular weight and
bioavailability leading to the equation:
mPTH 1 34 ðÞ  Pabs 1 34 ðÞ
MPTH 1 34 ðÞ ¼
mPTH 1 84 ðÞ  Pabs 1 84 ðÞ
MPTH 1 84 ðÞ
(where M is the molecular weight of PTH, Pabs the
bioavailability, and m the mass of PTH).
Using this calculation, 100 µg of PTH(1-84) is equivalent
to 25 μg of teriparatide {100 μg×(55/95)×4,115/9,426=
25 μg} and these are the approximate doses used in the
treatment of postmenopausal osteoporosis.
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